Your Position: Home
> Alzheimer's Disease Therapeutic Targets Alzheimer's Disease Therapeutic Targets
| Protein Name | Alternative Names | BioChemical Class / Role | Products (Cat NO)![]() |
||
| Protein | Antibody | Gene cDNA clones | |||
| GSK3B | GSK3beta isoform | GSK3B was originally identified as an enzyme that regulates glycogen synthesis and glucose storage in response to insulin, and more recently was rediscovered as a key regulatory component involved in energy metabolism, neuronal cell development, and body pattern formation, as well as tumorigenesis. Studies in mice show that overexpression of GSK3B gene may be relevant to the pathogenesis of Alzheimer disease. | 10044-H07B | HG10044-M | |
| HTR4 | HG10753-M | ||||
| BACE1 | ASP2, BACE, FLJ90568, HSPC104, KIAA1149 | As a member of the peptidase A1 protein family, BACE1 is a type I single-pass membrane glycoprotein and aspartic protease that is found mainly in the Golgi. which is the major constituent of amyloid plaques in the brains of individuals afflicted with Alzheimers disease (AD), and accordingly, BACE1 is implicated in the onset and progression of AD. | 10064-H02H 10064-H08H 10064-HCCH 50002-M08H |
10064-MM01 10064-MM02 10064-RP03 |
HG10064-M MG50002-M |
| Beta-Amyloid/Abeta | ABETA, APPI, protease nexin II, PN2, AAA, ABPP, AD1, CTFgamma, CVAP | Amyloid precursor protein (APP) is a type I transmembrane protein expressed in many tissues and concentrated in the synapses of neurons. APP can be processed by two different proteolytic pathways. In one pathway, APP is cleaved by β- and γ-secretase to produce the Beta-Amyloid protein which is the principal component of the amyloid plaques, the major pathological hallmark of Alzheimer’s disease (AD), while in the other pathway | 10703-H02H | HG10703-M | |
| IL-1 alpha | IL1F1, IL1A, IL-1A, IL1, IL1-ALPHA | Interleukin 1 (IL-1) is an important cytokine mediator involved in a variety of biological processes including immune responses, inflammatory, and promoting tissue degradation. IL-1 comprises two proteins, designated as IL-1 alpha and IL-1 beta which are encoded by distinct genes, and bind the same surface receptors with high affinity. Elevated levels of IL-1 alpha have been associated with a number of chronic disorders, including rheumatoid arthritis and Alzheimer’s disease, and therefore, may provide novel targets for therapeutic approaches aimed at controlling inflammatory processes. | 10128-HNCH | HG10128-M MG50114-M |
|
| IL-1 beta | IL1F2, IL1B, IL-1, IL1-BETA | Interleukin 1 (IL-1) is a family of polypeptide cytokines consisting of two agonists, IL-1 alpha (IL-1F1) and IL-1 beta (IL-1F2) encoded by two distinct genes and perform identical biological functions. IL-1 beta is produced by activated macrophages as a proprotein, which is proteolytically processed to its active form by caspase 1 (CASP1/ICE). This cytokine is an important mediator of the inflammatory response, and is involved in a variety of cellular activities, including cell proliferation, differentiation, and apoptosis. | 10139-HNAE | HG10139-M MG50101-M |
|
| p38 alpha/MAPK14 | p38, CSBP1, CSBP2, Mxi2, PRKM14, PRKM15, RK, CSPB1, SAPK2A, EXIP, RP1-179N16.5 | Four alternatively spliced transcript variants of p38 have been reported, p38 alpha (also known as MAPK14) is the best characterized isoform. p38 alpha/MAPK14 is activated following exposure to products of microbial pathogens, physical-chemical stimuli and cytokines. Furthermore, the p38 alpha/MAPK14 has been suggested to play a critical role linking developmental and stress-induced erythropoiesis through regulation of Epo expression. | 10081-H08B 10081-H07B 10646-HNCB |
HG10081-M HG10646-M |
|
| ECE1 | ECE, ECE-1 | HG10887-M | |||
+86-400-890-9989




